Different morphological structures of breast tumors demonstrate individual drug resistance gene expression profiles by Gerashchenko, T.S. et al.
228 Experimental Oncology 40, 228–234, 2018 (September)
DIFFERENT MORPHOLOGICAL STRUCTURES OF BREAST 
TUMORS DEMONSTRATE INDIVIDUAL DRUG RESISTANCE GENE 
EXPRESSION PROFILES
T.S. Gerashchenko1, 2, E.V. Denisov1, 2, *, N.M. Novikov1, 3, L.A. Tashireva4, E.V. Kaigorodova4, 
O.E. Savelieva2, 4, M.V. Zavyalova4, N.V. Cherdyntseva1, 2, V.M. Perelmuter4
1Laboratory of Molecular Oncology and Immunology, Cancer Research Institute,  
Tomsk National Research Medical Center, Tomsk 634050, Russia
2Laboratory for Translational Cellular and Molecular Biomedicine,  
Tomsk State University, Tomsk 634050, Russia
3Department of Cytology and Genetics, Tomsk State University, Tomsk 634050, Russia
4Department of General and Molecular Pathology, Cancer Research Institute,  
Tomsk National Research Medical Center, Tomsk 634050, Russia
Aim: To identify gene expression profiles involved in drug resistance of different morphological structures (tubular, alveolar, solid, 
trabecular, and discrete) presented in breast cancer. Material and Methods: Ten patients with luminal breast cancer have been 
included. A laser microdissection-assisted microarrays and qRT-PCR were used to perform whole-transcriptome profiling of dif-
ferent morphological structures, to select differentially expressed drug response genes, and to validate their expression. Results: 
We found 27 differentially expressed genes (p < 0.05) encoding drug uptake (SLC1A3, SLC23A2, etc.) and efflux (ABCC1, ABCG1, 
etc.) transporters, drug targets (TOP2A, TYMS, and Tubb3), and proteins that are involved in drug detoxification (NAT1 and 
ALDH1B1), cell cycle progression (CCND1, AKT1, etc.), apoptosis (CASP3, TXN2, etc.), and DNA repair (BRCA1 and USP11). 
Each type of structures showed an individual gene expression profile related to resistance and sensitivity to anticancer drugs. How-
ever, most of the genes (19/27; p < 0.05) were expressed in alveolar structures. Functional enrichment analysis showed that drug 
resistance is significantly associated with alveolar structures. Other structures demonstrated the similar number (10–13 out of 27) 
of expressed genes; however, the spectrum of resistance and sensitivity to different anticancer drugs varied. Conclusion: Different 
morphological structures of breast cancer show individual expression of drug resistance genes.
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The problem of cancer heterogeneity constitutes 
a significant diagnostic and therapeutic challenge. Intra-
tumor diversity implies the coexistence of different popu-
lations (subclones) with individual genetic alterations that 
affect their phenotype and biological behavior including, 
for example, ability to respond to chemotherapy.
Breast cancer (BC) represents an attractive model 
to study the influence of intratumor heterogeneity 
on chemotherapy response. BC comprises a highly 
heterogeneous group of diseases that is composed 
of different histological types with distinct morphologies 
and behaviors. The most widespread form of BC, inva-
sive carcinoma no special type (IC NST), is represented 
by different architectural arrangements of tumor cells 
or morphological structures: tubular, alveolar, solid, 
trabecular, and discrete groups [1]. Such intratumor 
morphological heterogeneity is a common phenom-
enon in IC NST. Up to 80% of IC NST shows the presence 
of 3–5 different types of morphological structures [2].
BC treatment is well-known to be challenging 
due to multidrug resistance and corresponding drug 
inefficacy [3]. Our previous studies showed that neo-
adjuvant chemotherapy (NAC) efficiency of BC sig-
nificantly depends on the intratumor morphological 
heterogeneity. A poor response to NAC is associated 
with the presence of alveolar, trabecular, or discrete 
groups in breast tumors, while the association was 
more significant in premenopausal patients. In con-
trast, a good response to chemotherapy was found 
in BCs with solid structures [2].
Molecular features of morphological structures that 
could explain their role in chemotherapy susceptibility 
are still unclear. Previously, we found that genes en-
coding ABC transporters are differentially expressed 
between various morphological structures [4]. Our 
resent study showed that different morphological 
structures represent transcriptionally distinct popula-
tions of tumor cells with varying degrees of epithelial-
mesenchymal transition and stemness [5]. Based 
on these results, we assumed that various morpho-
logical structures carry specific characteristics which 
modify chemotherapy efficiency.
Thus, in this study, we aimed to assess gene ex-
pression features of different morphological structures 
in BC that contribute to their drug susceptibility and 
to describe a drug resistance/sensitivity profile of each 
structure.
MATERIALS AND METHODS
Patients and samples. Ten patients with IC NST 
of luminal subtypes (age range 40–65; mean age 
53.00 ± 9.28) diagnosed and treated in the Cancer 
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Research Institute of Tomsk NRMC (Tomsk, Russia) 
were enrolled in the study. All cases did not receive 
any preoperative therapy. Clinical and pathological 
characteristics are shown in Table 1.
Fresh samples of the breast tumor and adjacent 
normal tissues were obtained during surgery, placed 
in liquid nitrogen and stored at −80 °C until laser mi-
crodissection. The procedures followed in this study 
were in accordance with the Helsinki Declaration 
(1964, amended in 1975 and 1983). Ethical approval 
was obtained by the ethical committee of Cancer 
Research Institute, Tomsk NRMC. Approval reference 
is 10 (29 September 2011). All patients signed an in-
formed consent for voluntary participation.
Laser microdissection and RNA isolation. All 
five types of morphological structures were observed 
in 7 out of 10 cases, whereas tubular structures were 
absent in the three patients (Table 1). Tubular, alveolar, 
solid, trabecular structures (50–120 samples of each 
structure), and discrete groups of tumor cells (300–
350 samples) were identified (Fig. 1, a) and isolated 
from 5 μm-thick hematoxylin and eosin stained sec-
tions of frozen tumor samples using PALM MicroBeam 
laser capture microdissection (Carl Zeiss, Germany). 
In addition, normal ducts (90–120 samples) were iso-
lated from sections of normal breast tissue samples. 
In total, we obtained 47 microdissected samples 
of different structures (10 samples each of alveolar, 
solid, trabecular, and discrete groups and 7 samples 
of tubular structures) and 10 samples of normal ducts.
RNA was extracted from the microdissected sam-
ples by RNeasyPlus Micro Kit (Qiagen, USA) according 
to the manufacturer’s instructions. RNA integrity num-
ber (RIN) was assessed using the 2200 Tape Station 
instrument and High Sensitivity RNA ScreenTape 
(Agilent, USA). Average RIN of samples was 5.6.
Microarray analysis. Three biological replicates 
of each type of morphological structures and normal 
breast epithelia (18 samples in total) were enrolled 
in gene expression profiling. In addition, each sample 
analyzed by gene expression microarrays was repre-
sented by tens and hundreds of structures of the same 
type (90–120 tubular, 90–120 alveolar, 90–120 tra-
becular, 50–60 solid, and 300–350 discrete groups). 
Other words, each sample contained many replicates 
of the same structures.
RNA samples of the microdissected samples were 
amplified using the Ovation PicoSL WTA System V2 kit 
(NuGEN, USA). Transcriptome profiling was performed 
using the SurePrint G3 Human GE v2, 8×60K micro-
arrays (Agilent, USA), scanning — using a SureScan 
Microarray Scanner (Agilent, USA). All procedures 
were performed as previously described [5]. The 
microarray data is available in the Gene Expression 
Omnibus (GEO, GSE80754). The stored data were 
evaluated using the R software (R Development Core 
Team, 2008) and the limma package from Bioconduc-
tor [6]. Log mean spot signals were taken for further 
analysis. Expression levels were normalized to normal 
breast epithelia (ducts).
qRT-PCR. RNA samples of the microdissected 
samples of 7 cases (39 samples in total; Table 1) 
were subjected to reverse transcription, ligation, and 
whole transcriptome amplification (QuantiTect Whole 
Transcriptome kit, Qiagen, USA). The amplified cDNA 
was used for qRT-PCR analysis of five genes (ABCG1, 
SLC25A13, SLC23A2, NAT1, and PIK3C3) to validate 
gene expression microarrays. qRT-PCR conditions, 
the temperature profile, and the algorithm for cal-
culating expression levels are given in our previous 
study [7]. The results were presented as log2 fold-
changes in the expression of the gene of interest 
relative to housekeeping genes (ACTB1 and GAPDH) 
and normal breast epithelia.
Statistical and functional enrichment analy-
ses. A moderated t-statistic as implemented in the 
limma package was used to rank genes for differential 
expression between each type of morphological struc-
tures and normal breast epithelia. The Pearson cor-
relation coefficient was used to assess the correlation 
between gene expression levels obtained by microar-
rays and qRT-PCR. Up- and down-regulated genes 
with |log-fold-change| ≥ log21.5 and an unadjusted 
p-value < 0.05 were used in functional enrichment 
analysis by Qiagen’s Ingenuity Pathway Analysis (IPA, 
Qiagen). The disease and functions analysis within IPA 
results was applied to find processes associated with 
drug resistance and the results were discussed using 
the following values: -log10 (p-value), or a negative 
log of the p-value derived from the Fisher’s Exact test.
RESULTS AND DISCUSSION
Based on the data of gene expression microarrays 
of different morphological structures, we estimated 
the expression of genes that are involved in the main 
mechanisms of drug susceptibility: drug uptake, efflux, 
and detoxification, the presence of drug targets, cell 
cycle arrest, apoptosis, and DNA repair.
Table 1. Clinicopathological characteristics of BC patients included in gene expression microarrays and qRT-PCR
Cases Age (yr) Grade TNM Molecular subtype ER PR HER2 Ki-67, % Morphological structures Analysis
1 46 2 T2N0M0 Lum B HER2− + + 0 34 all structures Gene expres-
sion micro-
array
2 40 2 T2N2M0 Lum B HER2− + + 1+ 24 all structures
3 49 2 T2N0M0 Lum B HER2+ + + 2+ 45 all structures
4 59 2 T2N3M0 Lum B HER2+ + + 2+ 38 all structures
qRT-PCR
5 49 2 T1N0M0 Lum B HER2− + + 1+ 37 all structures
6 65 2 Т1N0M0 Lum A + + 1+ 19 all structures
7 42 3 T1N1M0 Lum B HER2− + + 1+ 24 alv, sol, trab, discr
8 53 1 T1N0M0 Lum B HER2− + - 0 34 alv, sol, trab, discr
9 62 2 T2N0M0 Lum B HER2− + - 0 27 all structures
10 65 1 T2N0M0 Lum B HER2− + + 1+ 25 alv, sol, trab, discr
Note: TNM — tumor-node-metastasis classification; Lum — luminal; yr — years; ER — estrogen receptors; PR — progesterone receptors; “+” — presence; “-” — 
absence; tub — tubular; alv — alveolar; sol — solid; trab — trabecular; discr — discrete. HER2+ status was complemented by FISH analysis.
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First, we assessed the expression of genes 
(ABCB1, GSTP1, CYP, BAX, etc.) that were described 
to play a critical role in tumor drug resistance/sensi-
tivity. Surprisingly, no significant differential expres-
sion of these genes was observed between various 
structures. Some genes were absent in morphological 
structures whereas others were not significantly under- 
or overexpressed. However, there were exceptions 
such as ABCG2 and GSTP1 genes whose expression 
was considerably down-regulated in all structures 
excluding discrete groups of tumor cells. These 
structures also showed the significant up-regulation 
of SCL1A1 and SLC7A2 genes. In addition, the APC 
gene was substantially overexpressed only in trabecu-
lar structures (Table 2).
Second, given the above-mentioned results, 
we performed an additional analysis of the gene ex-
pression microarrays and found other genes that also 
contribute to susceptibility to anticancer drugs accord-
ing to the literature data (Table 3). In Fig. 1, b, we sum-
marized genes whose expression was significantly dif-
ferential between different morphological structures. 
Most of the drug response genes (19 out of 27) were 
found to be considerably expressed in alveolar struc-
tures, whereas other morphological structures dem-
onstrated almost similar number of expressed genes. 
In particular, 13 genes were significantly expressed 
in solid and trabecular structures and 10 — in tubular 
and discrete groups of tumor cells (Fig. 1, b).
Functional enrichment analysis of under- and over-
expressed genes (the expressional level > 1.5 or –1.5, 
р < 0.05) in morphological structures also showed 
an increased drug resistance profile of alveolar 
structures. In particular, the processes such as “drug 
resistance of cells” and “chemotherapy resistance 
of carcinoma cell lines” were significantly associ-
Fig. 1. Expression levels of drug resistance and sensitivity genes in different morphological structures. (a) Hematoxylin and eosin 
stained section of the breast tumor with different morphological structures (left): tubular (Tub), alveolar (Alv), solid (Sol), trabecular 
(Trab), and discrete (Discr) and their 3D immunofluorescence images (right). Tubular structures are represented by the tube-
shaped aggregations of tumor cells. Alveolar structures have a rounded (spheroidal) shape and contain up to 30 tumor cells. Solid 
structures are represented by the large shapeless groups of tens and hundreds of tumor cells. Trabecular structures are formed 
by one or two rows of tumor cells. Discrete groups of tumor cells are defined by arrangements of 2–5 cells and/or single cells. 
Red color indicates the cytoplasmic expression of cytokeratin 7, blue — DAPI staining (nucleus) [5]. (b) Expression levels of drug 
resistance and sensitivity genes in different morphological structures. ND — not determined; *expression level at p < 0.05. The 
color intensity is proportional to gene expression levels from low (green) to high (red). (c) The panel of resistance and sensitivity 
of different morphological structures of IC NST to anticancer drugs. The scales (1–3 and 1–4) show the number of overexpressed 
genes associated with sensitivity and resistance to any drug. Anthracyclines (doxorubicin and epirubicin), taxanes (paclitaxel), 
and platinum drugs (cisplatin)
a
b c
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ated only with alveolar structures (-log10 (p-value) = 
3.16 and 3.33, respectively; data not shown).
Finally, we validated the expression levels of five drug 
response genes (ABCG1, SLC25A13, SLC23A2, NAT1, 
and PIK3C3) yielded by microarrays using quantitative 
real-time polymerase chain reaction (qRT-PCR). The 
gene expression was positively correlated between 
microarrays and PCR (r = 0.73; p < 0.05, Fig. 2).
Table 3. Differentially expressed drug resistance and sensitivity genes in different morphological structures of IC NST
Drug resistance mechanisms Gene symbol Full gene name R/S* Drugs affected Ref.
Drug uptake SLC1A3 Solute Carrier Family 1 Member 3 R cisplatin [8]
SLC23A2 Solute Carrier Family 23 Member 2 R 5FU [9, 10]
SLC25A13 Solute Carrier Family 25 Member 13 S camptothecin [9]
SLC29A2 Solute Carrier Family 29 Member 2 R gemcitabine, fludarabine [11]
Drug efflux ABCA12 ATP Binding Cassette Subfamily A Member 12 R 5FU, paclitaxel [12]
ABCC1 ATP Binding Cassette Subfamily C Member 1 R etoposide, CPA,  doxorubicin, methotrexate
[12, 13]
ABCC11 ATP Binding Cassette Subfamily C Member 11 R 5FU [12, 14]
ABCG1 ATP Binding Cassette Subfamily G Member 1 R doxorubicin [12]
Drug detoxification NAT1 N-Acetyltransferase 1 R etoposide [15]
ALDH1B1 Aldehyde Dehydrogenase 1 Family Member B1 R CPA [16, 17]
The presence of drug targets TOP2A DNA Topoisomerase II Alpha S anthracyclines [18]
TYMS Thymidylate Synthetase S 5FU [19]
Tubb3 Tubulin Beta 3 Class III S taxanes [20]
Cell cycle arrest CDKN2D Cyclin Dependent Kinase Inhibitor 2D R cisplatin [21]
CCND1 Cyclin D1 R tamoxifen [22]
PIK3C3 Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 R tamoxifen [23, 24]
AKT1 AKT Serine/Threonine Kinase 1 R cisplatin [25]
PLK1 Polo Like Kinase 1 R trastuzumab, paclitaxel [26]
UBE2S Ubiquitin Conjugating Enzyme E2 S S taxanes [27]
Apoptosis TXN2 Thioredoxin 2 S tamoxifen [28]
XPO1 Exportin 1 R doxorubicin, etoposide [29]
mir-31 MicroRNA 31 R paclitaxel [30]
CASP3 Caspase 3 S cisplatin, doxorubicin,  etoposide
[31]
BRI3BP BRI3 Binding Protein R etoposide [32]
USP15 Ubiquitin Specific Peptidase 15 S paclitaxel [33]
DNA repair BRCA1 BRCA1, DNA repair associated S paclitaxel [34]
R cisplatin, etoposide
USP11 Ubiquitin Specific Peptidase 11 R paclitaxel, doxorubicin,  epirubicin
[35]
Note: R — resistance; S — sensitivity; 5FU — 5-fluorouracil; CPA — cyclophosphamide; Ref. — references; *in gene overexpression.
Table 2. Expression levels of drug resistance and sensitivity genes in different morphological structures of BC
Drug resistance mechanisms Genes Tub Alv Sol Trab Discr
Drug uptake
SLC19A1 ND 0.85 0.48 0.36 0.45
SLC29A1 –0.52 –1.47 –1.42 –2.37 –0.35
SLC1A1 3.78* 3.18* 3.59* 3.48* 2.6
SLC7A2 3.06* 3.16* 4.11* 3.08* 1.57
SLC7A11 1.7 3.29* 3.32* 1.83 3.21*
Drug efflux
ABCB1 0.38 –0.61 ND 1.27  –0.68
ABCB4  –0.68 –0.38 –1.11 –1.4 ND
ABCB5 0.34 ND –0.27 0.71 –0.27
ABCC3 –0.50 1.38 1.29 1.51 1.04
ABCC5 1.62 1.24 1.37 1.91 1.84
ABCG2  –2.8* –2.7* –2.1* –2.38* –1.33
Drug detoxification
DPYD –0.70 –0.97 –1.1 –0.4 –0.44
CYP3A5 –0.53 –1.02 ND ND –0.64
CYP2D6 0.24 0.5 0.37 1.07 0.29
CYP2C8 ND –0.33 0.62 0.62 –0.33
GSTP1 –2.96* –3.39* –2.1* –2.6* –0.4
CYP1A –0.56 0.57 0.32 1.6 –0.32
CYP2C9 –0.53 –0.46 –0.42 –0.38 ND
The presence of drug targets TOP1 0.85 ND 0.48 –0.52 ND
Cell cycle arrest
CCNE1 –2.32 –1.23 –1.99 –1.30 0.95
CDK2 1.64 ND ND 0.4 0.57
CDK4 0.32 0.7 0.82 0.41 ND
CDKN1A ND ND –0.55 –0.65 ND
CDKN2A 2.11 0.96 1.81 0.67 2.23
Apoptosis
BAD 2.2 1.52 1.78 –0.97 0.45
TP53 ND –0.96 –0.83 –1.46 ND
BAX –0.32 ND –0.46 –1.78 0.34
APC 0.79 ND 2.4 3.11* 0.69
CFLAR 0.13 0.25 0.19 0.19 0.43
Bcl2 ND 0.62 1.14 –0.50 1.74
DNA repair
BRCA2 –0.64 0.26 –0.24 –0.57 –0.43
ERCC1 –0.97 –1.22 –1.56 –1.06 –1.95
ERCC3 –0.56 –2.18 –1.38 –0.77 ND
ATM 0.98 ND 0.29 –0.36 1.41
XPA –0.86 0.77 ND 2.54 –1.68
XPC –2.71* –2.22* –1.9* –1.34 –0.39
MSH2 0.84 ND 1.02 0.44 –1.90
Note: Tub — tubular; Alv — alveolar; Sol — solid; Trab — trabecular; Discr — discrete; ND – not determined; *expression level at p < 0.05.
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In general, the microarray data showed that all 
structures display common gene expression fea-
tures. This includes increased drug detoxification 
through overexpression of the NAT1 gene and drug 
efflux through the ABCA12 and ABCC11 genes as well 
as taxane sensitivity through the high expression 
of the Tubb3 gene. Nevertheless, each morphological 
structure had specific drug susceptibility features. The 
expression of genes involved in the inhibition of drug-
induced apoptosis was frequently observed in alveolar 
and solid structures. Alveolar structures also showed 
upregulation of cell cycle genes, whereas trabecu-
lar structures more often displayed overexpression 
of drug uptake genes.
Despite the fact that most drug insensitivity genes 
were expressed in alveolar structures, total tumor 
chemoresistance is probably formed by the contribu-
tion of each type of morphological structures. Below, 
we summarized information about drug resistance 
and sensitivity features of different morphological 
structures in IC NST.
Tubular structures showed the significant over-
expression of 10 genes involved in resistance to 5-fluoro-
uracil, capecitabine, etoposide, cisplatin, and tamoxifen 
(Fig. 1, b, c). Despite the afore-mentioned resistance, 
these structures displayed sensitivity to 5-fluorouracil 
and capecitabine as well as taxanes. It is of note that 
tubular structures were not characterized by expression 
of genes associated with resistance to anthracyclines, 
cyclophosphamide and others (Fig. 1, c) that makes 
these agents appropriate to be prescribed for the the-
rapy of BCs composed of these morphological variants.
Alveolar structures were characterized by the sig-
nificant expression of the broadest panel of 19 genes 
that confer resistance to almost all therapeutic agents 
used in the treatment of BC patients (Fig. 1, b, c). 
For example, only alveolar structures showed simul-
taneous expression of four ABC transporter genes: 
ABCG1, ABCC1, ABCA12 and ABCC11 (Fig. 1, b), 
which efflux 5-fluorouracil, taxanes, anthracyclines, 
methotre xate, cyclophosphamide, and etopo-
side [12–14]. This probably explains the association 
of these structures with a lack of clinical response 
to NAC [2, 4, 36]. Given these data, the choice 
of an effective strategy to treat BCs containing al-
veolar structures is challenging. Nevertheless, these 
structures may be susceptible to camptothecin due 
to underexpression of the SLC25A13 which is un-
able to transfer this drug into mitochondria for its 
metabolism [9, 37] as well as to tamoxifen despite 
the PIK3C3 overexpression. Previous results sug-
gested the involvement of the PIK3C3 overexpression 
in tamoxifen and anthracycline resistance through 
activation of autophagy [23, 24]; however, further 
studies are needed to confirm this.
Solid structures demonstrated the significant 
expression of 13 genes involved in chemotherapy 
response (Fig. 1, b). The distinctive feature of solid 
structures was the expression of 5 key genes: TYMS, 
Tubb3, BRCA1, TOP2A, and CASP3 that provide sus-
ceptibility to a broad spectrum of drugs (Fig. 1, c). 
In addition, the CASP3 gene associated with drug-
induced apoptosis was considerably overexpressed 
only in solid structures (Fig. 1, b). These obser-
vations together with the data provided in Fig. 1, 
c indicate that solid structures possess resistance 
to trastuzumab, tamoxifen, and gemcitabine as well 
as simultaneous insensitivity and susceptibility 
to 5-fluorouracil, taxanes, anthracyclines, etopo-
side, and platinum-based drugs (Fig. 1, c). Thus, 
one may assume that solid structures are rather 
chemosensitive than drug-resistant. This sugges-
tion is also supported by the fact that the presence 
of solid structures in breast tumors of premeno-
pausal patients is associated with a good response 
to chemotherapy [2].
Trabecular structures showed the considerable 
expression of 13 genes that modulate drug response 
(Fig. 1, b). The distinctive feature of these structures 
was the significant underexpression of 3 of 4 SLC 
transporters: SLC25A13, SLC23A2, and SLC1A3 that 
are responsible for uptake of camptothecin, 5-fluo-
rouracil, and platinum-based drugs [8–10]. The 
TXN2 gene implicated in tamoxifen resistance [28] 
was strongly overexpressed only in trabecular struc-
tures (Table 3, Fig. 1, b). In addition, DNA repair genes 
were either absent (BRCA1) or not considerably up-
regulated (USP11) in these morphological structures 
(Fig. 1, b). Probably, these expression features, namely 
a decreased work of SLC transporters, as well as other 
characteristics (Fig. 1, b, c), may explain the previous 
results about the association of trabecular structures 
with a poor response to NAC [2, 4, 36]. Nevertheless, 
it seems that trabecular structures can be sensitive 
to anthracyclines (Fig. 1, c) because of overexpression 
of the TOP2A gene as well as no well-defined role of the 
PIK3C3 gene in resistance to this drug as indicated 
above. In addition, SLC25A13 underexpression may 
be a marker for camptothecin sensitivity (Fig. 1, c). 
Interestingly, we did not find high expression of the 
ABCB1 gene in trabecular structures as found in our 
previous study [4]. However, earlier work [4] did not 
Fig. 2. Correlation between gene expression microarrays and 
qRT-PCR. Plot shows the log mean spot signals and the log-
transformed expression levels of 5 genes detected by gene ex-
pression microarrays (y-axis) and qRT-PCR (x-axis), respectively
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apply statistical processing to find if the ABCB1 gene 
was significantly under- or overexpressed in trabecu-
lar structures compared to normal breast epithelia. 
Moreover, the previous study [4] enrolled patients 
with luminal A BC.
Discrete groups of cells were characterized by the 
significant expression of 10 genes involved in chemo-
therapy response (Fig. 1, b, c). The distinctive feature 
of these structures was a low activity of drug sensitivity 
genes (Fig. 1, b). In particular, discrete groups showed 
the considerable overexpression of only Tubb3 gene 
which is a clinical marker of sensitivity to taxanes [20]. 
The recent study described discrete groups of tumor 
cells as associated with low NAC effectiveness in pre-
menopausal patients [2]. Most likely, it can be related 
to the prevalence of drug resistance genes including 
ABCC11, ABCA12, SLC23A2, and etc. and almost 
complete absence of chemosensitivity markers 
(Fig. 1, b, c). In addition, the highly heterogeneous 
composition of these morphological structures [5] 
may contribute to drug resistance and should be con-
sidered when an appropriate chemotherapy regimen 
is chosen.
It should be noted that drug resistance and sensi-
tivity of different morphological structures mentioned 
above has a couple of drawbacks. First, the data 
discussed here concern so-called intrinsic drug re-
sistance (that is presented before treatment) because 
BC cases included in the gene expression profiling 
were NAC-naïve. Second, only genes which signifi-
cantly under- and overexpressed (p < 0.05) in morpho-
logical structures compared to normal breast epithelia 
were used to make the drug resistance and sensitivity 
panel (Fig. 1, c). Nevertheless, other genes modulating 
drug response were also expressed in various mor-
phological structures (Table 2), but differences were 
not significant. Third, the role of some genes provided 
in Table 3 and used for the construction of the drug 
susceptibility profile is not well-defined and further 
investigations are required.
CONCLUSION
Various morphological structures of IC NST previ-
ously described as transcriptionally distinct popula-
tions of tumor cells and to be associated with the che-
motherapy efficacy differ amongst themselves in the 
expression of drug resistance and sensitivity genes. 
Simply stated, different morphological structures show 
individual drug susceptibility profiles. The most drug-
resistant phenotype is typical for alveolar structures 
which were earlier found to be implicated in NAC inef-
ficiency [2, 4, 36], whereas solid structures are more 
drug sensitive and were previously associated with 
a good response to chemotherapy [2]. In addition, 
each type of structures shows resistance and sensi-
tivity to certain therapeutic agents that are associated 
with expression of specific genes. For example, alveo-
lar structures may be susceptible to camptothecin and 
tamoxifen but are tolerant to 5-fluorouracil, taxanes 
and etc. Trabecular structures probably show potential 
sensitivity to camptothecin and anthracyclines and 
resistance to other drugs. Overall, different morpho-
logical structures contribute to the intrinsic drug resis-
tance of BC and their assessment represent a simple 
method of predicting response to chemotherapy and 
an additional criterion for the selection of adequate 
therapy regimens.
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